Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 51Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Stomach Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 8Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Neoplasm Metastasis 5Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Nasopharyngeal Carcinoma 3Laryngeal Neoplasms 3HER2-positive Breast Cancer 3Fallopian Tube Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Solid Tumors 2Sarcoma 2Osteosarcoma 2

Interventions

Cyclophosphamide 9X-Rays 8Specimen Handling 8Phantoms, Imaging 7fludarabine 6Magnetic Resonance Spectroscopy 6cabozantinib 5Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Gemcitabine 4Doxorubicin 4irinotecan sucrosofate 3fludarabine phosphate 3Vincristine 3Temozolomide 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2mifamurtide 2larotrectinib 2ivosidenib 2ensartinib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × Docetaxel × 90 days × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

NCT06935409 2026-04-09

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Hansoh BioMedical R&D Company

Phase 3 Active not recruiting
117 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡